OBJECTIVE: The management of aggressive pituitary macroadenomas represents a
challenge to neurosurgeons. These tumors are very difficult to treat, owing mainly to their …

Temozolomide is effective in some patients with progressive pituitary adenoma or
carcinoma. We report a survey study of Italian patients treated with Temozolomide because …

We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years,
presenting aggressive pituitary tumors. In all the patients tested O6‐methylguanine‐DNA …

Pituitary adenomas are benign intracranial neoplasms that are frequently well-controlled
with standard treatments that include surgical resection, radiotherapy, and agents that …

To highlight the potential of temozolomide (TMZ) to induce rapid tumor regression in patients
with aggressive corticotroph adenomas (CA) that are refractory to surgery and radiation …

Objective The prognosis of either pituitary carcinoma or aggressive pituitary adenoma
resistant to standard therapies is poor. We assessed the efficacy of treatment with …

Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

Introduction Temozolomide (TMZ) is an oral alkylating agent that has been used over the
past 8 years to treat aggressive pituitary tumors resistant to conventional therapy. To date …

Objective Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is an
alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …

Object Aggressive pituitary adenomas frequently require multimodality treatment including
pituitary-suppressive medications, microsurgery, and radiation therapy or radiosurgery. The …